-
BMS Full Year 2025 Financial Report
BMS
Bristol Myers Squibb reports 2025 results with stable revenue, a sharp rebound in profitability, strong growth from new products, and resilient Eliquis sales reaching $14.4 billion despite patent pressures.
-
Global Biopharma Layoffs February 2026
Layoffs
Global Biopharma companies including GSK, IO Biotech, and Bitterroot Bio announce workforce reductions in February 2026 as part of cost-saving and strategic realignments, impacting research, technology, and leadership roles across their operations.
-
Global Biopharma Layoffs July 2025
Layoffs
Biopharmaceutical industry sees major July layoffs, with companies like Sarepta, GSK, Century, and Sage Therapeutics cutting jobs amid restructurings, trial setbacks, and M&A activity.
-
Cigna Files Antitrust Suit Over Pomalyst Monopoly
BMS
Cigna has filed a major antitrust lawsuit against Bristol Myers Squibb, accusing the company of anti-competitive tactics to delay generic competition for the blockbuster drug Pomalyst, costing payers billions.
-
Bristol Myers Defends Cobenfy Amid Setbacks
BMS
Bristol Myers defends its antipsychotic drug Cobenfy despite a failed phase 3 trial and slowing prescriptions. The company remains optimistic, citing physician support and ongoing trials in Alzheimer’s, bipolar disorder, and autism.
-
Bristol Myers Squibb Bets on ACP3 in $1.35B Deal
BMS
Bristol Myers Squibb teams up with Philochem in a $1.35B radiopharma deal to develop OncoACP3, a novel prostate cancer therapy targeting ACP3, offering a potential alternative to PSMA-focused treatments.
-
-
-
BMS's Q1 2025 Financial report
Market Trend
Bristol Myers Squibb Q1 2025 earnings: revenue down 6% YoY, but strong product performance drives EPS growth. Full-year guidance raised. Highlights include Opdivo, Reblozyl, and Breyanzi.
-
应城市|
桃园县|
陕西省|
阿拉尔市|
稻城县|
石台县|
扎赉特旗|
吴旗县|
宁化县|
墨玉县|
南平市|
大姚县|
瑞安市|
镇远县|
忻州市|
宜阳县|
大兴区|
开封市|
庆城县|
通化县|
陆河县|
神木县|
江都市|
沅江市|
波密县|
南投县|
古交市|
黑龙江省|
清丰县|
绥江县|
五大连池市|
鹤岗市|
广昌县|
桑植县|
灵川县|
华蓥市|
独山县|
剑河县|
简阳市|
巫溪县|
海口市|